StreetInsider.com News Articles

Form S-8 Evolus, Inc.

Tue, 03 Mar 2026 17:08:00 -0500

si-local-file:///var/storage/secattach/20260303/26103531.html

Form S-8 Evolus, Inc.

Tue, 03 Mar 2026 17:08:00 -0500

si-local-file:///var/storage/secattach/20260303/26103531.html

Form 10-K Evolus, Inc. For: Dec 31

Tue, 03 Mar 2026 17:02:00 -0500

si-local-file:///var/storage/secattach/20260303/26103360.html

Form 10-K Evolus, Inc. For: Dec 31

Tue, 03 Mar 2026 17:02:00 -0500

si-local-file:///var/storage/secattach/20260303/26103360.html

Form 8-K Evolus, Inc. For: Mar 03

Tue, 03 Mar 2026 16:30:00 -0500

si-local-file:///var/storage/secattach/20260303/26102048.html

Form 8-K Evolus, Inc. For: Mar 03

Tue, 03 Mar 2026 16:30:00 -0500

si-local-file:///var/storage/secattach/20260303/26102048.html

Evolus (EOLS) Misses Q4 EPS by 4c, provides guidance

Tue, 03 Mar 2026 16:10:08 -0500

Evolus (NASDAQ: EOLS) reported Q4 EPS of $0.00, $0.04 worse than the analyst estimate of $0.04. Revenue for the quarter came in at $90.3 million versus the consensus estimate of $90.75 million.

GUIDANCE:

Evolus sees FY2026 revenue of $327-337 million, versus the consensus of $329.7 million.

For earnings history and earnings-related data on Evolus (EOLS) click here.

Evolus (EOLS) Misses Q4 EPS by 4c, provides guidance

Tue, 03 Mar 2026 16:10:08 -0500

Evolus (NASDAQ: EOLS) reported Q4 EPS of $0.00, $0.04 worse than the analyst estimate of $0.04. Revenue for the quarter came in at $90.3 million versus the consensus estimate of $90.75 million.

GUIDANCE:

Evolus sees FY2026 revenue of $327-337 million, versus the consensus of $329.7 million.

For earnings history and earnings-related data on Evolus (EOLS) click here.

Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability¹ Beginning in 2026

Tue, 03 Mar 2026 16:05:00 -0500

Total Net Revenue of $90.3 Million for the Fourth Quarter and $297.2 Million for the Full-Year 2025, Representing Growth of 14% and 12% Over the Prior Year
Delivered GAAP Operating Income of $4.2 Million for the Fourth Quarter; Non-GAAP Operating Income of $7.1 Million for Q4 2025, Above Prior Guidance Range
Full-Year GAAP Operating Expenses of $229.8 Million in 2025; Non-GAAP Operating Expense of $209.7 Million, Within the Company’s Guidance Range of $208 Million to $213 Million, with Second Half 2025 Expenses Declining 4% Compared to the First Half, Driving Meaningful Year-Over-Year Operating Leverage in the Second Half
2026 Net Revenue Guidance

Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability¹ Beginning in 2026

Tue, 03 Mar 2026 16:05:00 -0500

Total Net Revenue of $90.3 Million for the Fourth Quarter and $297.2 Million for the Full-Year 2025, Representing Growth of 14% and 12% Over the Prior Year

Delivered GAAP Operating Income of $4.2 Million for the Fourth Quarter; Non-GAAP Operating Income of $7.1 Million for Q4 2025, Above Prior Guidance Range

Full-Year GAAP Operating Expenses of $229.8 Million in 2025; Non-GAAP Operating Expense of $209.7 Million, Within the Company’s Guidance Range of $208 Million to $213 Million, with Second Half 2025 Expenses Declining 4% Compared to the First Half, Driving Meaningful Year-Over-Year Operating Leverage in the Second Half

2026 Net Revenue Guidance

Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability¹ Beginning in 2026

Tue, 03 Mar 2026 16:05:00 -0500

Total Net Revenue of $90.3 Million for the Fourth Quarter and $297.2 Million for the Full-Year 2025, Representing Growth of 14% and 12% Over the Prior Year

Delivered GAAP Operating Income of $4.2 Million for the Fourth Quarter; Non-GAAP Operating Income of $7.1 Million for Q4 2025, Above Prior Guidance Range

Full-Year GAAP Operating Expenses of $229.8 Million in 2025; Non-GAAP Operating Expense of $209.7 Million, Within the Company’s Guidance Range of $208 Million to $213 Million, with Second Half 2025 Expenses Declining 4% Compared to the First Half, Driving Meaningful Year-Over-Year Operating Leverage in the Second Half

2026 Net Revenue Guidance

Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability¹ Beginning in 2026

Tue, 03 Mar 2026 16:05:00 -0500

Total Net Revenue of $90.3 Million for the Fourth Quarter and $297.2 Million for the Full-Year 2025, Representing Growth of 14% and 12% Over the Prior Year

Delivered GAAP Operating Income of $4.2 Million for the Fourth Quarter; Non-GAAP Operating Income of $7.1 Million for Q4 2025, Above Prior Guidance Range

Full-Year GAAP Operating Expenses of $229.8 Million in 2025; Non-GAAP Operating Expense of $209.7 Million, Within the Company’s Guidance Range of $208 Million to $213 Million, with Second Half 2025 Expenses Declining 4% Compared to the First Half, Driving Meaningful Year-Over-Year Operating Leverage in the Second Half

2026 Net Revenue Guidance

Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability¹ Beginning in 2026

Tue, 03 Mar 2026 16:05:00 -0500

Total Net Revenue of $90.3 Million for the Fourth Quarter and $297.2 Million for the Full-Year 2025, Representing Growth of 14% and 12% Over the Prior Year

Delivered GAAP Operating Income of $4.2 Million for the Fourth Quarter; Non-GAAP Operating Income of $7.1 Million for Q4 2025, Above Prior Guidance Range

Full-Year GAAP Operating Expenses of $229.8 Million in 2025; Non-GAAP Operating Expense of $209.7 Million, Within the Company’s Guidance Range of $208 Million to $213 Million, with Second Half 2025 Expenses Declining 4% Compared to the First Half, Driving Meaningful Year-Over-Year Operating Leverage in the Second Half

2026 Net Revenue Guidance

Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability¹ Beginning in 2026

Tue, 03 Mar 2026 16:05:00 -0500

Total Net Revenue of $90.3 Million for the Fourth Quarter and $297.2 Million for the Full-Year 2025, Representing Growth of 14% and 12% Over the Prior Year

Delivered GAAP Operating Income of $4.2 Million for the Fourth Quarter; Non-GAAP Operating Income of $7.1 Million for Q4 2025, Above Prior Guidance Range

Full-Year GAAP Operating Expenses of $229.8 Million in 2025; Non-GAAP Operating Expense of $209.7 Million, Within the Company’s Guidance Range of $208 Million to $213 Million, with Second Half 2025 Expenses Declining 4% Compared to the First Half, Driving Meaningful Year-Over-Year Operating Leverage in the Second Half

2026 Net Revenue Guidance

Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability¹ Beginning in 2026

Tue, 03 Mar 2026 16:05:00 -0500

Total Net Revenue of $90.3 Million for the Fourth Quarter and $297.2 Million for the Full-Year 2025, Representing Growth of 14% and 12% Over the Prior Year

Delivered GAAP Operating Income of $4.2 Million for the Fourth Quarter; Non-GAAP Operating Income of $7.1 Million for Q4 2025, Above Prior Guidance Range

Full-Year GAAP Operating Expenses of $229.8 Million in 2025; Non-GAAP Operating Expense of $209.7 Million, Within the Company’s Guidance Range of $208 Million to $213 Million, with Second Half 2025 Expenses Declining 4% Compared to the First Half, Driving Meaningful Year-Over-Year Operating Leverage in the Second Half

2026 Net Revenue Guidance

Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability¹ Beginning in 2026

Tue, 03 Mar 2026 16:05:00 -0500

Total Net Revenue of $90.3 Million for the Fourth Quarter and $297.2 Million for the Full-Year 2025, Representing Growth of 14% and 12% Over the Prior Year

Delivered GAAP Operating Income of $4.2 Million for the Fourth Quarter; Non-GAAP Operating Income of $7.1 Million for Q4 2025, Above Prior Guidance Range

Full-Year GAAP Operating Expenses of $229.8 Million in 2025; Non-GAAP Operating Expense of $209.7 Million, Within the Company’s Guidance Range of $208 Million to $213 Million, with Second Half 2025 Expenses Declining 4% Compared to the First Half, Driving Meaningful Year-Over-Year Operating Leverage in the Second Half

2026 Net Revenue Guidance

Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability¹ Beginning in 2026

Tue, 03 Mar 2026 16:05:00 -0500

Total Net Revenue of $90.3 Million for the Fourth Quarter and $297.2 Million for the Full-Year 2025, Representing Growth of 14% and 12% Over the Prior Year

Delivered GAAP Operating Income of $4.2 Million for the Fourth Quarter; Non-GAAP Operating Income of $7.1 Million for Q4 2025, Above Prior Guidance Range

Full-Year GAAP Operating Expenses of $229.8 Million in 2025; Non-GAAP Operating Expense of $209.7 Million, Within the Company’s Guidance Range of $208 Million to $213 Million, with Second Half 2025 Expenses Declining 4% Compared to the First Half, Driving Meaningful Year-Over-Year Operating Leverage in the Second Half

2026 Net Revenue Guidance

Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability¹ Beginning in 2026

Tue, 03 Mar 2026 16:05:00 -0500

Total Net Revenue of $90.3 Million for the Fourth Quarter and $297.2 Million for the Full-Year 2025, Representing Growth of 14% and 12% Over the Prior Year

Delivered GAAP Operating Income of $4.2 Million for the Fourth Quarter; Non-GAAP Operating Income of $7.1 Million for Q4 2025, Above Prior Guidance Range

Full-Year GAAP Operating Expenses of $229.8 Million in 2025; Non-GAAP Operating Expense of $209.7 Million, Within the Company’s Guidance Range of $208 Million to $213 Million, with Second Half 2025 Expenses Declining 4% Compared to the First Half, Driving Meaningful Year-Over-Year Operating Leverage in the Second Half

2026 Net Revenue Guidance

Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability¹ Beginning in 2026

Tue, 03 Mar 2026 16:05:00 -0500

Total Net Revenue of $90.3 Million for the Fourth Quarter and $297.2 Million for the Full-Year 2025, Representing Growth of 14% and 12% Over the Prior Year

Delivered GAAP Operating Income of $4.2 Million for the Fourth Quarter; Non-GAAP Operating Income of $7.1 Million for Q4 2025, Above Prior Guidance Range

Full-Year GAAP Operating Expenses of $229.8 Million in 2025; Non-GAAP Operating Expense of $209.7 Million, Within the Company’s Guidance Range of $208 Million to $213 Million, with Second Half 2025 Expenses Declining 4% Compared to the First Half, Driving Meaningful Year-Over-Year Operating Leverage in the Second Half

2026 Net Revenue Guidance

Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability¹ Beginning in 2026

Tue, 03 Mar 2026 16:05:00 -0500

Total Net Revenue of $90.3 Million for the Fourth Quarter and $297.2 Million for the Full-Year 2025, Representing Growth of 14% and 12% Over the Prior Year

Delivered GAAP Operating Income of $4.2 Million for the Fourth Quarter; Non-GAAP Operating Income of $7.1 Million for Q4 2025, Above Prior Guidance Range

Full-Year GAAP Operating Expenses of $229.8 Million in 2025; Non-GAAP Operating Expense of $209.7 Million, Within the Company’s Guidance Range of $208 Million to $213 Million, with Second Half 2025 Expenses Declining 4% Compared to the First Half, Driving Meaningful Year-Over-Year Operating Leverage in the Second Half

2026 Net Revenue Guidance

Evolus to Participate in The Leerink Partners Global Healthcare Conference

Wed, 25 Feb 2026 08:00:00 -0500

NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its management team will participate in a fireside chat and investor meetings at the upcoming Leerink Partners Global Healthcare Conference in Miami, FL.
The fireside chat will take place on Wednesday, March 11, 2026, at 11:20 AM ET.
The fireside chat can be accessed on the Investor Relations page of the Evolus website here. A replay of the webcast will be available 90 days

Evolus to Participate in The Leerink Partners Global Healthcare Conference

Wed, 25 Feb 2026 08:00:00 -0500

NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its management team will participate in a fireside chat and investor meetings at the upcoming Leerink Partners Global Healthcare Conference in Miami, FL.
The fireside chat will take place on Wednesday, March 11, 2026, at 11:20 AM ET.
The fireside chat can be accessed on the Investor Relations page of the Evolus website here. A replay of the webcast will be available 90 days

Evolus to Participate in The Leerink Partners Global Healthcare Conference

Wed, 25 Feb 2026 08:00:00 -0500

NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its management team will participate in a fireside chat and investor meetings at the upcoming Leerink Partners Global Healthcare Conference in Miami, FL.
The fireside chat will take place on Wednesday, March 11, 2026, at 11:20 AM ET.
The fireside chat can be accessed on the Investor Relations page of the Evolus website here. A replay of the webcast will be available 90 days

Evolus to Participate in The Leerink Partners Global Healthcare Conference

Wed, 25 Feb 2026 08:00:00 -0500

NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its management team will participate in a fireside chat and investor meetings at the upcoming Leerink Partners Global Healthcare Conference in Miami, FL.
The fireside chat will take place on Wednesday, March 11, 2026, at 11:20 AM ET.
The fireside chat can be accessed on the Investor Relations page of the Evolus website here. A replay of the webcast will be available 90 days

Form 4 Evolus, Inc. For: Feb 17 Filed by: White Albert G III

Thu, 19 Feb 2026 20:58:00 -0500
si-local-file:///var/storage/secattach/20260219/26031875.html